阳光诺和：诉讼一审判决，恒生制药需付215.10万元研发费及违约金

Core Viewpoint - The company has filed a lawsuit against Hengsheng Pharmaceutical for overdue R&D fees, currently in the first-instance judgment stage [1] Group 1: Legal Proceedings - The court has ruled that Hengsheng Pharmaceutical must pay the company a total of 2.151 million yuan in overdue R&D fees along with corresponding late payment penalties, involving four separate lawsuits [1] - The penalties for each case are calculated based on different bases and timelines, with both parties sharing the litigation costs for some cases [1] - The company has fully provisioned for bad debts related to accounts receivable and contract assets from Hengsheng Pharmaceutical, indicating no negative impact on current or future profits from this lawsuit [1] Group 2: Current Status - As of the announcement date, the case is still within the appeal period, and the final execution status remains uncertain [1]